MicroRNA‑766 inhibits papillary thyroid cancer progression by directly targeting insulin receptor substrate 2 and regulating the PI3K/Akt pathway
- 1 November 2018
- journal article
- retracted article
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 54 (1), 315-325
- https://doi.org/10.3892/ijo.2018.4615
Abstract
MicroRNAs (miRNAs/miRs) are widely dysregulated in papillary thyroid cancer (PTC). Dysregulated miRNAs, together with their target genes, comprise a complex network that has been implicated in the regulation of PTC pathogenesis. Further knowledge of the functional roles of aberrantly expressed miRNAs in PTC, and the underlying molecular mechanisms, may assist in the identification of novel therapeutic targets. miR-766 has been well studied in human cancer; however, the expression status, specific roles and regulatory mechanisms of miR-766 in PTC remain unclear. The present study aimed to detect miR-766 expression in PTC tissues and cell lines, to explore the biological roles of miR-766 in the malignant biological behaviors of PTC cells, and to determine the underlying mechanism of action of miR-766 in PTC cells. The results revealed that miR-766 was downregulated in PTC tissues and cell lines, and its downregulation was strongly associated with TNM stage and lymph node metastasis. Overexpression of miR-766 inhibited PTC cell proliferation, colony formation, migration and invasion, promoted cell apoptosis and reduced tumor growth in vivo. Mechanistically, insulin receptor substrate 2 (IRS2) was identified as a direct target of miR-766 in PTC cells. IRS2 was upregulated in PTC tissues, and this was inversely correlated with miR-766 expression. Inhibition of IRS2 simulated the tumor suppressor activity of miR-766 in PTC cells. Restoration of IRS2 expression negated the tumor-suppressing effects of miR-766 overexpression on PTC cells. Notably, miR-766 directly targeted IRS2 to inhibit activation of the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) pathway in PTC cells in vitro and in vivo. Overall, these findings indicated that miR-766 may inhibit the malignant biological behaviors of PTC cells by directly targeting IRS2 and regulating the PI3K/Akt pathway, thus suggesting that this miRNA may be a promising therapeutic target for PTC.Keywords
This publication has 40 references indexed in Scilit:
- An eight-miRNA signature as a potential biomarker for predicting survival in lung adenocarcinomaJournal of Translational Medicine, 2014
- Insulin Receptor Substrate 2-mediated Phosphatidylinositol 3-kinase Signaling Selectively Inhibits Glycogen Synthase Kinase 3β to Regulate Aerobic GlycolysisOnline Journal of Public Health Informatics, 2014
- IRS2 is a candidate driver oncogene on 13q34 in colorectal cancerInternational Journal of Experimental Pathology, 2013
- IRS1 is highly expressed in localized breast tumors and regulates the sensitivity of breast cancer cells to chemotherapy, while IRS2 is highly expressed in invasive breast tumorsCancer Letters, 2013
- Emerging molecular therapies of advanced thyroid cancerMolecular Aspects of Medicine, 2010
- Comparative analysis of gene expression profiles of papillary thyroid microcarcinoma and papillary thyroid carcinomaJournal of Cancer Research and Therapeutics, 2010
- MicroRNA profiling as a tool to understand prognosis, therapy response and resistance in breast cancerEuropean Journal of Cancer, 2008
- MicroRNA Signatures in Human CancersNature Reviews Cancer, 2006
- MicroRNAs: small RNAs with a big role in gene regulationNature Reviews Genetics, 2004
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001